Real breakthroughs happen when the research brings together different skills, knowledge and passion. Discover an inspiring perspective on interdisciplinary approaches to CAR-T cell therapies in this episode of TJ Talks, which guests Professor Yael David, Head of the laboratory and associate member of the Programme in Chemical Biology at Memorial Sloan Kettering, interviewed by Dr Francesca De Santis.

The importance of an interdisciplinary approach lies in the fact that it combines chemistry, biology and epigenetics to overcome the limitations of CAR-T cell therapies, particularly in solid tumours, and the metabolic stress within the tumor microenvironment that can compromise the function of immune cells and make them less effective.

Through the development of engineering, computational and AI tools - Prof. David states - the research aims to protect the genetic material of T cells and reprogram their metabolic response. And its ultimate goal is to create next-generation cell therapies that are more resistant, able to adapt to hostile environments, and clinically effective for cancer patients.

Enjoy the TJ Talks podcast.

Real breakthroughs happen when the research brings together different skills, knowledge and passion. Discover an inspiring perspective on interdisciplinary approaches to CAR-T cell therapies in this episode of&nbsp;TJ&nbsp;Talks, which guests Professor Yael David, Head of the laboratory and associate member of the Programme in Chemical Biology at Memorial Sloan Kettering, interviewed by Dr Francesca De Santis.
The importance of an interdisciplinary approach lies in the fact that it combines chemistry, biology and epigenetics to overcome the limitations of CAR-T cell therapies, particularly in solid tumours, and the metabolic stress within the tumor microenvironment that can compromise the function of immune cells and make them less effective.
Through the development of engineering, computational and AI tools - Prof. David states - the research aims to protect the genetic material of T cells and reprogram their metabolic response. And its ultimate goal is to create next-generation cell therapies that are more resistant, able to adapt to hostile environments, and clinically effective for cancer patients.
Enjoy the&nbsp;TJ&nbsp;Talks podcast.

TJ Talks is an educational initiative featuring conversations about oncology led by Prof. Giancarlo Pruneri, Editor in Chief of Tumori Journal.

The podcast series aims to explore a variety of topics of interest that reflect the dynamic and evolving nature of oncology research, with contributions from renowned international experts and promising young researchers in the field. Through these insightful discussions, TJ Talks seeks to support the professional development of clinicians and researchers working to improve the cancer care.

Follow us on X, Bluesky and LinkedIn to always be updated on cancer research and clinical practice in oncology!

TJ Talks is an educational initiative featuring conversations about oncology led by Prof. Giancarlo Pruneri, Editor in Chief of Tumori Journal.
The podcast series aims to explore a variety of topics of interest that reflect the dynamic and evolving nature of oncology research, with contributions from renowned international experts and promising young researchers in the field. Through these insightful discussions, TJ Talks seeks to support the professional development of clinicians and researchers working to improve the cancer care.
Follow us on <a href="https://x.com/TumoriJ">X</a>, <a href="https://bsky.app/profile/tumorijournal.bsky.social">Bluesky</a> and&nbsp;<a href="https://www.linkedin.com/company/tumori-journal/">LinkedIn</a> to always be updated on cancer research and clinical practice in oncology!

TJ Talks

Conversations on trending topics in oncology hosted by the Editor-in-Chief of Tumori Journal, Prof. Giancarlo Pruneri.

Conversations on trending topics in oncology hosted by the Editor-in-Chief of Tumori Journal, Prof. Giancarlo Pruneri.